Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 3—March 2009
Perspective

Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries

David S. FedsonComments to Author 
Author affiliation: University of Virginia, Charlottesville, Virginia, USA (retired)

Main Article

Table 2

Recent studies of patients with pneumonia treated with statins*

Investigator (reference) Study design and population Principal outcome Adjusted odds ratio (95% CI) or % reduction (p value)
van der Garde et al. (17)
 Case–control diabetes patients, 4,719/15,322
 Pneumonia hospitalization
 0.50 (0.28-0.89)
Schlienger et al. (18) Case–control, 1,227/4,734 Pneumonia hospitalization 0.63 (0.46–0.88)
30-day pneumonia mortality rate
 0.47 (0.25–0.88)
Mortensen et al. (19)
 Retrospective cohort, 1,566/7,086
 30-day pneumonia mortality rate
 0.54 (0.42–0.70)
Chalmers et al. (20)
 Prospective cohort, 257/750
 30-day pneumonia mortality rate
 0.46 (0.25– 0.85)
Thomsen et al. (21)
 Retrospective cohort, 1,372/28,528
 30-day pneumonia mortality rate
 0.69 (0.58–0.82)
Majumdar et al. (22) Prospective cohort, 325/3,090 Hospital mortality rate and ICU admission (adjusted for administrative data) 0.88 (0.63–1.22)
Hospital mortality rate and ICU admission (adjusted for age, propensity score, clinical data, and functional status)
 1.10 (0.76–1.60)
Choi et al. (23) Randomized controlled trial, ICU treatment; 33 with atorvastatin and 34 controls ICU mortality rate 45.4 (0.08)
Hospital mortality rate 51.2 (0.026)

*Except for the inpatient randomized controlled trial of Choi et al (23), recent treatment in the observational studies was defined as a statin prescription within a period of 30 days (18) to 90 days before hospitalization for pneumonia. CI, confidence interval; ICU, intensive care unit.

Main Article

References
  1. Oshitani  H, Kamigaki  T, Suzuki  A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis. 2008;14:875–80. DOIPubMedGoogle Scholar
  2. Fedson  DS, Dunnill  P. From scarcity to abundance: pandemic vaccines and other agents for “have not” countries. J Public Health Policy. 2007;28:322–40. DOIPubMedGoogle Scholar
  3. World Health Organization. Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. WHO scientific consultation. 2007 Oct 1–3; Geneva [cited 2008 Dec 10]. Available from http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf
  4. Higgs  ES, Hayden  FG, Chotpitayasunondh  T, Whitworth  J, Farrar  J. The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. Antiviral Res. 2008;78:64–8. DOIPubMedGoogle Scholar
  5. Chen  LM, David  CT, Zhou  H, Cox  NJ, Donis  RO. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 2008;4:e1000072. DOIPubMedGoogle Scholar
  6. Belser  JA, Blixt  O, Chen  LM, Pappas  C, Maines  TR, Van Hoeven  N, Contemporary North America influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad Sci U S A. 2008;105:7558–63. DOIPubMedGoogle Scholar
  7. Reports of increased survival in bird flu patients taking Tamiflu. International Symposium on Respiratory Viral Infections; 2008 Mar 2; Singapore [cited 2008 Dec 10]. Available from http://www.antara.co.id/en/print/?i=1204536377
  8. Murray  CJL, Lopez  AD, Chin  B, Feehan  D, Hill  KH. Estimation of potential global influenza mortality on the basis of vital registry data from the 1918–1920 pandemic: a quantitative analysis. Lancet. 2006;368:2211–8. DOIPubMedGoogle Scholar
  9. Webster  RG, Campbell  CH. Studies on the origin of pandemic influenza. IV. Selection and transmission of “new” influenza viruses in vivo. Virology. 1974;62:404–13. DOIPubMedGoogle Scholar
  10. Fidler  DP. Influenza virus samples, international law, and global health diplomacy. Emerg Infect Dis. 2008;14:88–94. DOIPubMedGoogle Scholar
  11. Schnirring  L. Indonesia claims wide support for virus-sharing stance. Center for Infectious Disease and Research Policy News. 2008 May 27 [cited 2008 Dec 12]. Available from http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/may2708sharing.html
  12. Fedson  DS. New technologies for meeting the global demand for pandemic influenza vaccines. Biologicals. 2008;36:346–9. DOIPubMedGoogle Scholar
  13. Fedson  DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43:199–205. DOIPubMedGoogle Scholar
  14. Fedson  DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis. 2008;8:571–6. DOIPubMedGoogle Scholar
  15. Butler  D. Cheaper approaches to flu divide flu researchers. Nature. 2007;448:976–7. DOIPubMedGoogle Scholar
  16. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261–73.
  17. van de Garde  EM, Hak  E, Souverein  PC, Hoes  AW, van den Bosch  JM, Leufkens  HG. Statin therapy and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61:957–61. DOIPubMedGoogle Scholar
  18. Schlienger  RG, Fedson  DS, Jick  S, Jick  H, Meier  C. Statins and the risk of pneumonia: a population-based nested case-control study. Pharmacotherapy. 2007;27:325–32. DOIPubMedGoogle Scholar
  19. Mortensen  EM, Pugh  MJ, Copeland  L, Cornell  J, Restrepo  MI, Anzueto  A, Impact of statins and ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia and influenza. Eur Respir J. 2008;31:611–7. DOIPubMedGoogle Scholar
  20. Chalmers  JD, Singanayagam  A, Murray  MP, Hill  AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008;121:1002–7. DOIPubMedGoogle Scholar
  21. Thomsen  RW, Riis  A, Kornum  JB, Christensen  S, Johnsen  SP, Sorensen  HT. Preadmission use of statins and outcomes after hospitalization with pneumonia. Arch Intern Med. 2008;168:2081–7. DOIPubMedGoogle Scholar
  22. Majumdar  SR, McAlister  FA, Eurich  DT, Padwal  RS, Marrie  TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: a population based prospective cohort study. BMJ. 2006;333:999–1004. DOIPubMedGoogle Scholar
  23. Choi  HS, Park  MJ, Kang  HM, Lim  IH, Choi  CW, You  JH. Statin use and mortality in sepsis due to pneumonia. Crit Care Med. 2007;35(Suppl):1362. DOIPubMedGoogle Scholar
  24. Budd  A, Alleva  L, Alsharifi  M, Koskinen  A, Smytha  V, Mullbacher  A, Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother. 2007;51:2965–8. DOIPubMedGoogle Scholar
  25. Palamara  AT, Nencioni  L, Aquilano  K, De Chiara  G, Hernandez  L, Cossolino  F, Inhibition of influenza A virus replication by resveratrol. J Infect Dis. 2005;191:1719–29. DOIPubMedGoogle Scholar
  26. Song  JM, Park  KD, Lee  KH, Byun  YH, Park  JH, Kim  SH, Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res. 2007;76:178–85. DOIPubMedGoogle Scholar
  27. Siddiqui  AM, Cui  X, Wu  R, Dong  W, Zhou  M, Hu  M, The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med. 2006;34:1874–82. DOIPubMedGoogle Scholar
  28. Zheng  BJ, Chan  KW, Lin  YP, Zhao  GY, Chan  C, Zhang  HJ, Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008;105:8091–6. DOIPubMedGoogle Scholar
  29. Simmons  C, Farrar  JT. Insights into inflammation. N Engl J Med. 2008;359:1621–3. DOIPubMedGoogle Scholar
  30. McAuley  JL, Hornung  F, Boyd  KL, Smith  AM, McKeon  R, Bennick  J, Expression of the 1918 influenza A virus PB1–F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe. 2007;2:240–9. DOIPubMedGoogle Scholar
  31. Imai  Y, Kuba  K, Neely  GG, Yaghubian-Malhami  R, Perkmann  T, van Loo  G, Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133:235–49. DOIPubMedGoogle Scholar
  32. Mizgerd  JP, Skerrett  SJ. Animal models of human lung disease. Am J Physiol Lung Cell Mol Physiol. 2008;294:L387–98. DOIPubMedGoogle Scholar
  33. Fukunaga  K, Kohli  P, Bonnans  C, Fredenburgh  LE, Levy  BD. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol. 2005;174:5033–9.PubMedGoogle Scholar
  34. Korteweg  C, Gu  J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol. 2008;172:1155–70. DOIPubMedGoogle Scholar
  35. van der Poll  T, Opal  SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32–43. DOIPubMedGoogle Scholar
  36. Rittirsch  D, Flierl  MA, Ward  PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776–87. DOIPubMedGoogle Scholar
  37. Carré  JE, Singer  M. Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta 2008;1777:763–71.
  38. World Health Organization. WHO global conference on severe acute respiratory syndrome (SARS). Where do we go from here? 2003 Jun 17–18 [cited 2008 Dec 10]. Available from http://www.who.int/csr/sars/conference/june_2003/materials/report/en/index.html

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external